Guiding Sole Intraoperative Radiotherapy in Breast Cancer According to ASTRO Guidelines: Mitigating Adverse Outcomes in a Taiwan Single-Center

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Dec 31

PMID 39739750

Authors

Hsin-Yi Yang

Yuk-Wah Tsang

Chi-Wen Tu

Yu-Chen Hsu

Affiliations

Soon will be listed here.

Abstract

Background: Intraoperative radiotherapy (IORT) is considered a de-escalating adjuvant treatment for breast cancer low-risk patients. However, the broader criteria applied by the Taiwan IORT Study Cooperative Group led to an increased rate of locoregional recurrence (LRR) among patients receiving only IORT. Consequently, we revised the criteria for sole IORT treatment to include patients who meet the American Society for Radiation Oncology (ASTRO) eligibility standards. This study aims to investigate how aligning treatment strategies with ASTRO guidelines impacts oncological outcomes in patients receiving IORT.

Methods: From September 2014 to March 2022, a retrospective review of 632 patients with invasive breast cancer undergoing breast-conserving surgery assessed outcomes following External Beam Radiation Therapy (EBRT), sole IORT, or IORT combined with supplemental EBRT (IORT+boost), with a mean follow-up period of 4.71 ± 2.10 years. Strategic modifications following the ASTRO guidelines were implemented in April 2021 for sole IORT recipients.

Results: ASTRO-suitable patients had significantly lower rates of LRR (0.00% vs. 10.64%), distant metastasis (0.00% vs. 4.00%), and any recurrence (0.00% vs. 7.79%) than non-suitable patients (p < 0.05). After adjusting for confounders, the overall and non-suitable patients in the IORT group both exhibited significantly higher hazard ratios for LRR than those in the EBRT group, with values of 5.79 (95% confidence intervals (CI) = 1.75-19.18) and 5.48 (95% CI = 1.66-18.02), respectively.

Conclusions: Aligning treatment criteria with ASTRO guidelines for sole IORT significantly reduces locoregional recurrence rates in patients with invasive breast cancer, highlighting the efficacy of these strategic modifications in improving oncological outcomes.

References

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707-16. PMC: 3254252. DOI: 10.1016/S0140-6736(11)61629-2. View

Sanz J, Eraso A, Ibanez R, Williams R, Algara M . Tumor Bed Boost Radiotherapy in the Conservative Treatment of Breast Cancer: A Review of Intra-Operative Techniques and Outcomes. Cancers (Basel). 2023; 15(16). PMC: 10452620. DOI: 10.3390/cancers15164025. View

Brunt A, Haviland J, Sydenham M, Agrawal R, Algurafi H, Alhasso A . Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. J Clin Oncol. 2020; 38(28):3261-3272. PMC: 7526720. DOI: 10.1200/JCO.19.02750. View

Lai H, Liu L, Ouyang F, Yao C, Jan H, Chang Y . Multi-center study on patient selection for and the oncologic safety of intraoperative radiotherapy (IORT) with the Xoft Axxent® eBx® System for the management of early stage breast cancer in Taiwan. PLoS One. 2017; 12(11):e0185876. PMC: 5667880. DOI: 10.1371/journal.pone.0185876. View

Korzets Y, Fyles A, Shepshelovich D, Amir E, Goldvaser H . Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019; 175(3):531-545. DOI: 10.1007/s10549-019-05209-9. View

Wang L, Sun M, Yang S, Chen Y, Li T . Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer. Front Oncol. 2022; 11:737982. PMC: 8716392. DOI: 10.3389/fonc.2021.737982. View

Silverstein M, Kim B, Lin K, Lloyd S, Snyder L, Khan S . Risk-Adapted Intraoperative Radiation Therapy (IORT) for Breast Cancer: A Novel Analysis. Ann Surg Oncol. 2023; 30(10):6079-6088. PMC: 10495476. DOI: 10.1245/s10434-023-13897-3. View

Vaidya J, Wenz F, Bulsara M, Tobias J, Joseph D, Keshtgar M . Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2013; 383(9917):603-13. DOI: 10.1016/S0140-6736(13)61950-9. View

Giap F, Osteen L, Liu I, Spiguel L, Shaw C, Morris C . Intraoperative radiation therapy for early-stage breast cancer: a single-institution experience. Rep Pract Oncol Radiother. 2022; 27(4):666-676. PMC: 9521704. DOI: 10.5603/RPOR.a2022.0075. View

10.

Orecchia R, Veronesi U, Maisonneuve P, Galimberti V, Lazzari R, Veronesi P . Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. Lancet Oncol. 2021; 22(5):597-608. DOI: 10.1016/S1470-2045(21)00080-2. View

11.

Leonardi M, Maisonneuve P, Mastropasqua M, Morra A, Lazzari R, Rotmensz N . How do the ASTRO consensus statement guidelines for the application of accelerated partial breast irradiation fit intraoperative radiotherapy? A retrospective analysis of patients treated at the European Institute of Oncology. Int J Radiat Oncol Biol Phys. 2012; 83(3):806-13. DOI: 10.1016/j.ijrobp.2011.08.014. View

12.

Valente S, Tendulkar R, Cherian S, Shah C, Ross D, Lottich S . TARGIT-R (Retrospective): 5-Year Follow-Up Evaluation of Intraoperative Radiation Therapy (IORT) for Breast Cancer Performed in North America. Ann Surg Oncol. 2021; 28(5):2512-2521. DOI: 10.1245/s10434-020-09432-3. View

13.

Makower D, Lin J, Xue X, Sparano J . Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer. NPJ Breast Cancer. 2021; 7(1):20. PMC: 7921089. DOI: 10.1038/s41523-021-00231-x. View

14.

Agrawal R, Aird E, Barrett J, Barrett-Lee P, Bentzen S, Bliss J . The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008; 371(9618):1098-107. PMC: 2277488. DOI: 10.1016/S0140-6736(08)60348-7. View

15.

Stoian R, Exner J, Gainey M, Erbes T, Gkika E, Popp I . Comparison of intraoperative radiotherapy as a boost vs. simultaneously integrated boosts after breast-conserving therapy for breast cancer. Front Oncol. 2023; 13:1210879. PMC: 10318399. DOI: 10.3389/fonc.2023.1210879. View

16.

Shah C, Wilkinson J, Lyden M, Beitsch P, Vicini F . Predictors of local recurrence following accelerated partial breast irradiation: a pooled analysis. Int J Radiat Oncol Biol Phys. 2012; 82(5):e825-30. DOI: 10.1016/j.ijrobp.2011.11.042. View

17.

Anderson B, Arthur D, Hannoun-Levi J, Kamrava M, Khan A, Kuske R . Partial breast irradiation: An updated consensus statement from the American brachytherapy society. Brachytherapy. 2022; 21(6):726-747. DOI: 10.1016/j.brachy.2022.07.004. View

18.

Zhong Y, Tong F, Shen J . Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis. BMC Cancer. 2022; 22(1):102. PMC: 8787911. DOI: 10.1186/s12885-022-09193-0. View

19.

Fastner G, Gaisberger C, Kaiser J, Scherer P, Ciabattoni A, Petoukhova A . ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy with electrons (IOERT) in breast cancer. Radiother Oncol. 2020; 149:150-157. DOI: 10.1016/j.radonc.2020.04.059. View

20.

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366(9503):2087-106. DOI: 10.1016/S0140-6736(05)67887-7. View